• R21 CA223503 (Nassar / Privette Vinnedge, co-I) 8/1/2018 - 7/31/2020
    NIH
    Targeting the PTPase UBASH3B/Sts-1 as a Novel TNBC Therapy
  • R37 CA218072-01A1 (Privette Vinnedge) 02/08/18-01/31/25
    NIH
    Mechanisms Coupling DEK to Oncogenesis
  • Cancer Survivorship Pilot Award (Privette Vinnedge) 03/01/18-12/31/19
    University of Cincinnati Cancer Center
    Investigating DEK as a prognostic marker for secondary breast cancer in female survivors of pediatric Hodgkin’s lymphoma
  • No number assigned (Privette Vinnedge) 03/01/2018-12/31/2018
    Cincinnati Children’s Trustee Award
    Mechanisms Coupling DEK to Oncogenesis
  • R01 CA193549 (Komurov) 05/01/15-04/30/20
    NIH
    Exploiting Proteotoxic Stress in Therapy-Refractory HER2+ Breast Cancers